Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

The preferential metastasis of cancer cells to skeleton not only disrupts the process of bone remodeling and influences the therapeutic decision, but also results in severe complications. Although the current diagnosis of bone metastases (BM) relies on bone imaging techniques, they are not sensitive enough for early detection as well as they are invasive and expensive to use. Since factors derived from bone metabolism are potentially useful to diagnose metastatic bone disease in cancer patients, a number of clinical trials have been carried out on this area. Results suggest that higher levels of bone biomarkers are associated with an increased risk of BM. As a result, biochemical-markers are showing prospects in early diagnosis of BM. This review summarizes the available evidence on the clinical use of biochemical-markers in the diagnosis of various cancers with high incidence of BM including breast, prostate and lung. Copyright © 2011 Elsevier Ltd. All rights reserved.

Citation

Qian Huang, Xuenong Ouyang. Biochemical-markers for the diagnosis of bone metastasis: a clinical review. Cancer epidemiology. 2012 Feb;36(1):94-8

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 21474411

View Full Text